论文部分内容阅读
目的确定乙型肝炎病毒(HBV)基因型在山东地区的分布及拉米夫定抗病毒疗效的影响。方法采用PCR微板核酸分子杂交酶联显色技术,对临床服用拉米夫定一年的131例乙型肝炎患者血清中的HBV-DNA进行基因分型,与未服用拉米夫定组对照。结果治疗组C型为87.4%(90/103),D型为12.6%(13/103)。对照组C型为89.3%(25/28),D型为10.7%(3/28),两组间差异无统计学意义。均未发现A、B、E和F基因型。结论首次从临床慢性乙肝患者中得出山东地区HBV优势基因型为C基因型,同时存在D基因型。服用拉米夫定治疗一年对HBV基因型没有影响。
Objective To determine the distribution of hepatitis B virus (HBV) genotype in Shandong and the effect of lamivudine antiviral therapy. Methods The HBV microarray was used to genotype HBV-DNA in serum of 131 hepatitis B patients who took lamivudine for one year, and compared with the control group without lamivudine . Results In the treatment group, C type was 87.4% (90/103) and D type was 12.6% (13/103). The control group was 89.3% (25/28) in type C and 10.7% (3/28) in type D, with no significant difference between the two groups. No A, B, E and F genotypes were found. Conclusions For the first time from clinical chronic hepatitis B patients derived HBV dominant genotype C genotype in Shandong, there are D genotypes. Lamivudine treatment for one year had no effect on HBV genotypes.